ADMA BIOLOGICS, INC.
ADMALoading price...
Overview
Previous Close13.59
Open13.37
Ask11.43
Bid11.24
Day's Range10.90 - 13.51
52 Week Range10.90 - 25.67
PE Ratio(TTM)18.88
Market Cap2.7B
Volume22.71M
Avg. Volume2.86M
12 Months Earnings209.45M
12 Months Revenue488.56M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Revenue | 488.56M | 474.17M | 426.45M | 258.21M | 154.08M | 80.94M |
| Cost of Revenue | 221.28M | 222.86M | 206.90M | 169.27M | 118.81M | 79.77M |
| Gross Profit | 267.28M | 251.31M | 219.55M | 88.94M | 35.27M | 1.17M |
| Operating Expenses | 100.27M | 95.68M | 80.57M | 67.31M | 74.63M | 59.55M |
| Profit after Tax (Net Income) | 209.45M | 208.93M | 197.67M | -28.24M | -65.90M | -71.65M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Ramsey, United States
Website: https://www.admabiologics.com
Co-Founder, President, CEO & Director: Mr. Adam S. Grossman
Employees: 640
About Company:
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.